<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9736">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662505</url>
  </required_header>
  <id_info>
    <org_study_id>1230.26</org_study_id>
    <nct_id>NCT01662505</nct_id>
  </id_info>
  <brief_title>Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese
      patients with AML
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose based on the incidence of dose limiting toxicities</measure>
    <time_frame>up to 28 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission (CR)</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete remission with incomplete blood count recovery (CRi)</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission (PR)</measure>
    <time_frame>up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Volasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive escalating dose of volasertib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volasertib</intervention_name>
    <description>Patient to receive volasertib</description>
    <arm_group_label>Volasertib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with diagnosis of AML (except for acute promyelocytic leukemia, APL)
             according to the World Health Organization definition and with one of the following
             features at screening

               -  Relapsed or refractory AML

               -  Untreated AML patients not considered to be suitable for standard induction
                  therapy according to investigator's judgement

          2. Male or female patients of age &gt;/= 18 years at the time of informed consent

          3. Eastern Cooperative Oncology Group performance status score 0 - 2 at screening

          4. Signed written informed consent consistent with Japanese Good Clinical Practice.

        Exclusion criteria:

          1. Patients with APL

          2. Patients in the third or later relapse

          3. Prior stem cell transplantation

          4. Treatment with systemic therapy for the primary disease (including an investigational
             drug) within 14 days before the first dose of volasertib with the exception of
             hydroxyurea, or lack of recovery from any acute toxicities or clinically significant
             adverse events pertinent to the prior systemic therapy

          5. Treatment with gemtuzumab ozogamicin within 6 weeks before the first dose of
             volasertib

          6. Concomitant medication/treatment with anti-leukemic chemotherapy (systemic or
             intrathecal), radiotherapy, immunotherapy, or any investigational agent while
             receiving study treatment

          7. Other malignancy requiring treatment at the time of screening

          8. Clinical central nervous system (CNS) symptoms deemed by the investigator to be
             related to leukemic CNS involvement or requiring treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1230.26.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isehara, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maebashi, Gunma,</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagasaki, Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagoya-shi, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1230.26.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yoshida-gun, Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>August 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
